Green Tea Epigallocatechin Gallate Exhibits Anticancer Effect in Human Pancreatic Carcinoma Cells via the Inhibition of Both Focal Adhesion Kinase and Insulin-Like Growth Factor-I ReceptorReportar como inadecuado




Green Tea Epigallocatechin Gallate Exhibits Anticancer Effect in Human Pancreatic Carcinoma Cells via the Inhibition of Both Focal Adhesion Kinase and Insulin-Like Growth Factor-I Receptor - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Biomedicine and BiotechnologyVolume 2010 2010, Article ID 290516, 8 pages

Research Article

Consolidated Research Institute for Advanced Science and Medical Care ASMeW, Waseda University, Tokyo 169-8050, Japan

Division of Ultrafine Structure, Department of Pathology, Research Institute of International Medical Center of Japan, Toyama 1-21-1, Shinjuku-ku, Tokyo 162-8655, Japan

Faculty of Science and Engineering, Waseda University, Tokyo 169-8555, Japan

Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo 108-8639, Japan

Tea Solutions, Food Research Lab, Hara Office Inc, Miyabara, Fujieda City 130-0012, Japan

Received 10 November 2010; Accepted 29 December 2010

Academic Editor: Gary E. Gallick

Copyright © 2010 Hoang Anh Vu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The exact molecular mechanism by which epigallocatechin gallate EGCG suppresses human pancreatic cancer cell proliferation is unclear. We show here that EGCG-treated pancreatic cancer cells AsPC-1 and BxPC-3 decrease cell adhesion ability on micro-pattern dots, accompanied by dephosphorylations of both focal adhesion kinase FAK and insulin-like growth factor-1 receptor IGF-1R whereas retained the activations of mitogen-activated protein kinase and mammalian target of rapamycin. The growth of AsPC-1 and BxPC-3 cells can be significantly suppressed by EGCG treatment alone in a dose-dependent manner. At a dose of 100 μM which completely abolishes activations of FAK and IGF-1R, EGCG suppresses more than 50% of cell proliferation without evidence of apoptosis analyzed by PARP cleavage. Finally, the MEK1-2 inhibitor U0126 enhances growth-suppressive effect of EGCG. Our data suggests that blocking FAK and IGF-1R by EGCG could prove valuable for targeted therapy, which can be used in combination with other therapies, for pancreatic cancer.





Autor: Hoang Anh Vu, Yuuichi Beppu, Hoang Thanh Chi, Kousuke Sasaki, Hideaki Yamamoto, Phan Thi Xinh, Takashi Tanii, Yukihiko Hara

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados